Literature DB >> 24170628

Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses.

Ashok K Chaturvedi1, Susan T Weintraub, Jose L Lopez-Ribot, Floyd L Wormley.   

Abstract

Cryptococcus neoformans, the main causative agent of cryptococcosis, is a fungal pathogen that causes life-threatening meningoencephalitis in immunocompromised patients. To date, there is no vaccine or immunotherapy approved to treat cryptococcosis. Cell- and antibody-mediated immune responses collaborate to mediate optimal protection against C. neoformans infections. Accordingly, we identified cryptococcal protein fractions capable of stimulating cell- and antibody-mediated immune responses and determined their efficacy to elicit protection against cryptococcosis. Proteins were extracted from C. neoformans and fractionated based on molecular mass. The fractions were then evaluated by immunoblot analysis for reactivity to serum extracted from protectively immunized mice and in cytokine recall assays for their efficacy to induce pro-inflammatory and Th1-type cytokine responses associated with protection. MS analysis revealed a number of proteins with roles in stress response, signal transduction, carbohydrate metabolism, amino acid synthesis, and protein synthesis. Immunization with select protein fractions containing immunodominant antigens induced significantly prolonged survival against experimental pulmonary cryptococcosis. Our studies support using the combination of immunological and proteomic approaches to identify proteins that elicit antigen-specific antibody and Th1-type cytokine responses. The immunodominant antigens that were discovered represent attractive candidates for the development of novel subunit vaccines for treatment and/or prevention of cryptococcosis.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Cryptococcosis; Cryptococcus neoformans; Cytoplasmic proteins; Microbiology; Surface proteins; Vaccination

Mesh:

Substances:

Year:  2013        PMID: 24170628      PMCID: PMC3916089          DOI: 10.1002/pmic.201300213

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  68 in total

1.  Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans.

Authors:  Sonia Brena; Jonathan Cabezas-Olcoz; María D Moragues; Iñigo Fernández de Larrinoa; Angel Domínguez; Guillermo Quindós; José Pontón
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

Review 2.  Cells and cytokines in pulmonary cryptococcosis.

Authors:  G B Huffnagle; M F Lipscomb
Journal:  Res Immunol       Date:  1998 May-Jun

Review 3.  Cell wall and secreted proteins of Candida albicans: identification, function, and expression.

Authors:  W L Chaffin; J L López-Ribot; M Casanova; D Gozalbo; J P Martínez
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

4.  Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro.

Authors:  M Feldmesser; J Mukherjee; A Casadevall
Journal:  J Antimicrob Chemother       Date:  1996-03       Impact factor: 5.790

5.  Immunisation with the glycolytic enzyme enolase confers effective protection against Candida albicans infection in mice.

Authors:  Wen qing Li; Xu chu Hu; Xiaohuan Zhang; Yanping Ge; Sainan Zhao; Yan Hu; Robert B Ashman
Journal:  Vaccine       Date:  2011-06-07       Impact factor: 3.641

6.  Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice.

Authors:  Karen L Wozniak; Mattie L Young; Floyd L Wormley
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

7.  A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis.

Authors:  H Kakeya; H Udono; N Ikuno; Y Yamamoto; K Mitsutake; T Miyazaki; K Tomono; H Koga; T Tashiro; E Nakayama; S Kohno
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 8.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.

Authors:  J Mukherjee; M Feldmesser; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  18 in total

1.  Cryptococcal heat shock protein 70 homolog Ssa1 contributes to pulmonary expansion of Cryptococcus neoformans during the afferent phase of the immune response by promoting macrophage M2 polarization.

Authors:  Alison J Eastman; Xiumiao He; Yafeng Qiu; Michael J Davis; Priya Vedula; Daniel M Lyons; Yoon-Dong Park; Sarah E Hardison; Antoni N Malachowski; John J Osterholzer; Floyd L Wormley; Peter R Williamson; Michal A Olszewski
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

2.  Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens.

Authors:  Maureen M Hester; Chrono K Lee; Ambily Abraham; Payam Khoshkenar; Gary R Ostroff; Stuart M Levitz; Charles A Specht
Journal:  Vaccine       Date:  2019-11-04       Impact factor: 3.641

Review 3.  A Call to Arms: Quest for a Cryptococcal Vaccine.

Authors:  Marley C Caballero Van Dyke; Floyd L Wormley
Journal:  Trends Microbiol       Date:  2017-11-02       Impact factor: 17.079

4.  Identification of immunodominant proteins of the microalgae Prototheca by proteomic analysis.

Authors:  A Irrgang; C Weise; J Murugaiyan; U Roesler
Journal:  New Microbes New Infect       Date:  2014-11-08

5.  Well-known surface and extracellular antigens of pathogenic microorganisms among the immunodominant proteins of the infectious microalgae Prototheca zopfii.

Authors:  Alexandra Irrgang; Jayaseelan Murugaiyan; Christoph Weise; Walid Azab; Uwe Roesler
Journal:  Front Cell Infect Microbiol       Date:  2015-09-29       Impact factor: 5.293

6.  Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice.

Authors:  Ashok K Chaturvedi; Rumanasma S Hameed; Karen L Wozniak; Camaron R Hole; Chrissy M Leopold Wager; Susan T Weintraub; Jose L Lopez-Ribot; Floyd L Wormley
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

7.  Induction of Protective Immunity to Cryptococcal Infection in Mice by a Heat-Killed, Chitosan-Deficient Strain of Cryptococcus neoformans.

Authors:  Rajendra Upadhya; Woei C Lam; Brian Maybruck; Charles A Specht; Stuart M Levitz; Jennifer K Lodge
Journal:  mBio       Date:  2016-05-10       Impact factor: 7.867

8.  Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins.

Authors:  Jackson Champer; James I Ito; Karl V Clemons; David A Stevens; Markus Kalkum
Journal:  J Fungi (Basel)       Date:  2016-01-12

9.  Antifungal activity of dendritic cell lysosomal proteins against Cryptococcus neoformans.

Authors:  Benjamin N Nelson; Savannah G Beakley; Sierra Posey; Brittney Conn; Emma Maritz; Janakiram Seshu; Karen L Wozniak
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

Review 10.  Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections.

Authors:  C M Leopold Wager; F L Wormley
Journal:  Mucosal Immunol       Date:  2014-07-30       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.